UroGen Pharma (URGN) Could Be 57% Undervalued On Strong Third Quarter Results

Why UroGen Pharma's latest quarterly report matters

UroGen Pharma (URGN) just put out third quarter figures that show sales of US$89 million and a sharply smaller net loss, a combination that naturally puts the stock on investor watchlists.

UroGen Pharma’s recent rally, with a 1-day share price return of 6.3% to US$26.31, comes after the stock fell 28.6% over 30 days and 44.2% over 90 days. However, the 3-year total shareholder return of 123.7% and 5-year total shareholder return of 78.5% present a much stronger longer-run picture.

Spot fresh ideas around UroGen Pharma's latest move by scanning a curated group of biopharma stocks with resilient balance sheets and earnings profiles using the list of solid balance sheet and fundamentals (25 results).

Bulls point to UroGen Pharma’s sharp sales ramp and shrinking losses, while bears focus on the ongoing red ink and share volatility. Which side does the current valuation lean toward as you weigh the latest move?

Most Popular Narrative: 57% Undervalued

Against a last close of $26.31, the analyst consensus Narrative on Simply Wall St anchors UroGen Pharma’s fair value at $61.71. This points to a sizeable valuation gap that investors are actively trying to explain.

The current valuation is consistent with a view that the market is heavily discounting the potential of UroGen Pharma’s uro-oncology franchise and long-dated exclusivity, which some market participants see as indicating that the stock may be undervalued.

See why 15 investors see UroGen Pharma as 57% undervalued.

Result: Fair Value of $61.71 (UNDERVALUED)

Still, the recent JELMYTO guidance cut and UroGen Pharma’s high 2026 operating expense plans could both chip away at confidence in that undervalued story.

Find out about the key risks to this UroGen Pharma narrative.

Next Steps

Mixed signals on UroGen Pharma’s risk and reward profile make this a stock you need to evaluate directly and quickly using the 4 key rewards and 3 important warning signs 4 key rewards and 3 important warning signs

Looking for more investment ideas beyond UroGen Pharma?

If UroGen Pharma has your attention, do not stop at a single ticker. Let the wider opportunity set work for you through a focused stock screener.

• Target resilient balance sheets and cleaner fundamentals by scanning a list of solid balance sheet and fundamentals (25 results) tailored to financially grounded companies.
• Hunt for mispriced quality by running a 33 high quality undervalued stocks that surfaces stocks trading below their assessed worth.
• Prioritize stability and income potential by reviewing a 6 dividend fortresses built around higher-yield payouts.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com